Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.48) by 11.11 percent. This is a 20.9 percent increase over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $22.000 thousand which missed the analyst consensus estimate of $666.667 thousand by 96.70 percent.